Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03375320 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 630 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Completion pushed from Aug 19, 2026 to Sep 1, 2027 Secondary endpoints: details revised at 3 of 3 entries · Study description revised · Site details revised at 34 of 432 sites Show 3 more changesShow less
    • Secondary endpoints: details revised at 3 of 3 entries
    • Study description revised
    • Site details revised at 34 of 432 sites
  2. Study sites: 433 to 432v629
  3. Study sites revised (433)v628 See this version in full on ClinicalTrials.gov ↗
  4. 3 versions Re-verified since May 12, 2026, no change to tracked fieldsv625-v627
  5. Study sites: 434 to 433v624
Show 43 earlier versionsHide 43 earlier versions
  1. 27 versions Re-verified since Mar 3, 2026, no change to tracked fieldsv597-v623
  2. Study sites revised (434)v596 See this version in full on ClinicalTrials.gov ↗
  3. Study sites revised (434)v595 See this version in full on ClinicalTrials.gov ↗
  4. Study sites: 436 to 434v594
  5. Completion date: Nov 22, 2025 to Aug 19, 2026 Study sites revised (436)v593 Show 1 more changeShow less
    • Study sites revised (436)

    See this version in full on ClinicalTrials.gov ↗

  6. Study sites revised (436)v592 See this version in full on ClinicalTrials.gov ↗
  7. Study sites revised (436)v591 See this version in full on ClinicalTrials.gov ↗
  8. Re-verified, no change to tracked fieldsv590
  9. Study sites revised (436)v589 See this version in full on ClinicalTrials.gov ↗
  10. Re-verified, no change to tracked fieldsv588
  11. Completion date: May 3, 2025 to Nov 22, 2025 Interventions: Cabozantinib S-malate (Drug), Computed Tomography (Procedure), Magnetic Resonance Imaging (Procedure), Placebo Administration (Other)… to Biospecimen Collection (Procedure), Cabozantinib S-malate (Drug), Computed Tomography (Procedure), Magnetic Resonance Imaging (Procedure)… · Study sites revised (436)v587 Show 2 more changesShow less
    • Interventions: Cabozantinib S-malate (Drug), Computed Tomography (Procedure), Magnetic Resonance Imaging (Procedure), Placebo Administration (Other)… to Biospecimen Collection (Procedure), Cabozantinib S-malate (Drug), Computed Tomography (Procedure), Magnetic Resonance Imaging (Procedure)…
    • Study sites revised (436)

    See this version in full on ClinicalTrials.gov ↗

  12. Study sites revised (436)v586 See this version in full on ClinicalTrials.gov ↗
  13. Re-verified, no change to tracked fieldsv585
  14. Study sites revised (436)v584 See this version in full on ClinicalTrials.gov ↗
  15. Study Status, Contacts/Locationsv583
  16. Results first posted: Oct 16, 2024 Secondary endpoints: details revised at 1 of 3 entriesv582 Show 1 more changeShow less
    • Secondary endpoints: details revised at 1 of 3 entries
  17. Enrollment target: 296 to 298v581
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.
Trial Details
NCT Number NCT03375320
Lead Sponsor National Cancer Institute (NCI)
Conditions Functioning Pancreatic Neuroendocrine Tumor, Intermediate Grade Lung Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Neoplasm, Locally Advanced Digestive System Neuroendocrine Tumor G1, Locally Advanced Lung Neuroendocrine Neoplasm, Locally Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm, Low Grade Lung Neuroendocrine Neoplasm +20 more
Enrollment 298 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov